Всего найдено: 2

Occurrence frequency of contrast-associated acute kidney injury after coronary artery stenting in STEMI men with new coronavirus infection (COVID-19)

DOI: https://doi.org/10.25512/DIR.2023.17.1.01

For quoting:
Bocharov A.V., Gruzdeva A.A., Tibilov A.M., Popov L.V. "Occurrence frequency of contrast-associated acute kidney injury after coronary artery stenting in STEMI men with new coronavirus infection (COVID-19) ". Journal Diagnostic & interventional radiology. 2023; 17(1); 8-15.

authors:

Bocharov A.V.

Gruzdeva A.A.

Tibilov A.M.

Popov L.V.

keywords:

COVID-19

SARS-CoV-2

STEMI

acute kidney injury

percutaneous coronary interventions

Frequency of occurrence of no-reflow syndrome in STEMI patients with occlusive coronary artery thrombosis

DOI: https://doi.org/10.25512/DIR.2022.16.4.04

For quoting:
Bocharov A.V., Tibilov A.M., Popov L.V. "Frequency of occurrence of no-reflow syndrome in STEMI patients with occlusive coronary artery thrombosis ". Journal Diagnostic & interventional radiology. 2022; 16(4); 40-45.

authors:

Bocharov A.V.

Tibilov A.M.

Popov L.V.

keywords:

acute myocardial infarction

no-reflow

coronary artery thrombosis

percutaneous coronary intervention

Abstract:

Aim: was to compare results of using of direct stenting and coronary artery stenting after pre-dilation (CSaPD) in STEMI patients with occlusive coronary artery thrombosis in terms of frequency of no-reflow syndrome and adverse cardiovascular events (MACE) during in-hospital period.

Material and methods: study included 620 patients with acute myocardial infarction with elevation of the ST segment of the electrocardiogram and occlusive thrombosis of the infarct-dependent coronary artery, who successfully underwent endovascular revascularization by stenting. The CSaPD group included 297 patients who underwent stenting after a preliminary balloon angioplasty. The direct stenting group consisted of 323 patients who underwent stenting without prior dilation. The primary endpoint of the study was the occurrence of no-reflow syndrome, secondary endpoints were cardiac death, certain stent thrombosis, recurrence of myocardial infarction, as well as the combined MACE point. Patients of both groups were monitored during in-hospital period.

Results: there were no significant differences between the groups of CSaPD and direct stenting in main clinical-demographic and clinical-angiographic indicators, with the exception of the average length of hospitalization (11 [8;12] vs 8 [7;9], respectively, p = 0,04). Endpoint analysis revealed differences in the incidence of no-reflow syndrome (34 (11,45%) vs 9 (2,79%) in the CSaPD and direct stenting groups, respectively, p = 0,03), cardiac death (31 (10,44%) vs 7 (2,17%) in the CSaPD and direct stenting groups, respectively, p = 0,04), as well as the combined MACE point (37 (12,46%) vs 8 (2,48%) in the CSaPD and direct stenting groups, respectively, p = 0,02).

Conclusion: in STEMI patients with occlusive coronary artery thrombosis, direct stenting of the infarct-dependent artery during the restoration of coronary blood flow to TIMI I after passage of coronary guide-wire, significantly reduces the incidence of no-reflow syndrome (34 (11,45%) vs 9 (2,79%) in the CSaPD and direct stenting, respectively, p = 0,03) and cardiac death (31 (10,44%) vs 7 (2,17%) in the CSaPD and direct stenting groups, respectively, p = 0,04).